Volume 11 million, including the last trade @ .0008. Wonder if we get some news this month regarding the OTC mess?

I’d settle for a few sentences from Dave regarding if there’s any progress with the OTC, and how goes the business. Hopefully when all is settled, we’ll be talking about a penny stock again as we once did.

Let’s start with Q3. As well, looking forward to when the Holladay’s are removed from the list of officials. More importantly, how’s the business/ contracts going? Are the labs ( assuming there’s more than one) going full steam ahead? An update would be nice to see.

Most likely he will post something only when there’s something to post. Mid January he did post on X that operations were normal.

Perhaps the news will be so good, that many will “buy the news”. Whatever the reason, nice to see the PPS moving up.

Nice to see 7’s/ 8’s going.

Always appreciate your posting . I see we have 7’s that are trading. Looking forward to dropping that first zero and eventually heading to dropping another zero along the way. For what it’s worth, I believe Dave is working hard to make his company a success, despite all the challenges & disappointments in 2024.

Good morning Varok, & all shareholders, care to elaborate. Tia

Volume up today. I see there are 6’s on the bid.

On OTC, as of Jan 9, doesn’t appear to be any change to the share structure. But then again, who knows if it has been officially updated. FWIW, still hopeful Dave comes through for us.

Same here, but in the meantime, not fun seeing 1.9 million sold off at .0004.

Same here, but in the meantime, not fun seeing 1.9 million sold off at .0004.

Thanks for sharing. Fwiw, picked up some fives last week.

No further news, no tweets since mid December, no volume, etc. Sure hope while we’re waiting for whatever that their labs are going full tilt. I wonder what’s going on with all the previous announced contracts?

Assuming there are still a few others that are shareholders besides myself, wondering if we’ll get some positive news starting next week? As well, a healthy, peaceful and happy New Year to all.

As of yesterday, the PPS is “ fill in the blanks”….

As of December 9, there doesn’t appear to be a change in the share structure.

Couldn’t agree with you more.

Thought with the early positive volume we’d be moving up, but obviously not. Still not giving up on Dave & the Company. Hanging in.

Hopefully whatever is going on is and will be extremely positive. Hopefully we find out what’s going on before the end of the year if that’s realistic. Can’t wait to drop that 1st zero and head towards that second zero. Trying to stay positive despite the sickening PPS.

Would be nice to see the OTC situation cleared up before Xmas.

I thought this company would be different but as you say probably close to 98% plus turn out to be either scams or they don’t have what it takes to survive. Personally, I don’t think Dave was out to screw us. Could have, should have, but didn’t sell, so here I sit.

So much for some of us thinking awhile back this gem was eventually heading towards 01. Will we ever get a bounce back for those of us that still have some shares?

.00045 says it all

Branded Legacy, Inc. Strengthens Biotech Leadership, Focuses on Expansion, and Advances Strategic Rebranding


2024-12-05 08:30 ET - News Release

ORLANDO, Fla., Dec. 05, 2024 (GLOBE NEWSWIRE) -- via IBN -- Branded Legacy, Inc (OTC.PK: BLEG), provides updates as it confronts recent challenges and charts a focused path forward. The company has reaffirmed its commitment to the biotech and wellness sectors, with its primary focus now on expanding its wholly owned subsidiary, Sycamore BioPharma.

Addressing Recent Challenges

Branded Legacy recently endured a targeted attack that temporarily compromised its digital assets, including critical platforms such as banking and OTC accounts access. This malicious act, orchestrated in part by former employees, not only disrupted operations but also resulted in delays and reduction of profit from a major contract projected to generate over $10 million in revenue. Coupled with hurricane-related operational disruptions and shipping delays at the company's Florida facilities, these challenges have significantly impacted the company's short-term operations and financial outlook.

In response, Branded Legacy has taken decisive action to secure its digital assets, remove individuals involved in the attack, and restructure its operations. Released subsidiaries include The Alcannabist LLC, Rocket Web Development and Design LLC, and All In Extracts LLC. All executives associated with these subsidiaries have been removed from their positions and are no longer associated with the company. Branded Legacy is now focused on overcoming these setbacks by concentrating its efforts and resources on Sycamore BioPharma, its flagship subsidiary.

Strategic Focus on Sycamore BioPharma

Sycamore BioPharma, acquired by Branded Legacy eight months ago, has become the cornerstone of the company's growth strategy. Renowned for its development of innovative wellness solutions, Sycamore BioPharma aligns seamlessly with Branded Legacy's commitment to quality, natural ingredients, and scientific excellence. With a focus on expanding Sycamore's operations and pipeline, Branded Legacy is positioning itself to capture new market opportunities and drive long-term success.

To support this renewed focus, Branded Legacy has entered discussions for the sale of MariJ Pharmaceuticals Inc. Revenue from this sale will be used to offset dilution moving forward, as we fund Sycamore's continued development and operational expansion. Additionally, we have determined that a raise of the authorized share count will be necessary to offset any funding gaps from the MariJ sale. This will ensure the company can execute its strategic objectives, recover from the impact of lost revenue, and pursue new growth opportunities in the biotech and wellness markets.

Looking to the Future

Despite recent setbacks, Branded Legacy remains steadfast in its mission. The company is advancing late-stage discussions to supply one-fifth of Europe's CBD market, an initiative that could significantly expand its international footprint. Our specific goal is to scale up to production of 3 tons of CBD isolate monthly, with 1.5 tons being exported to the European Union and 1.5 tons sold domestically through existing channels. In addition, the company is moving forward with its rebranding initiative, transitioning its name and symbol to Royal Enterprises, Inc. (ROYL) to reflect its evolution and renewed focus.

"These challenges have only strengthened our resolve," stated CEO Dave Oswald. "While the actions of former employees have created significant hurdles, our commitment to growth and innovation remains unwavering. By focusing on our more successful subsidiaries and securing the necessary funding to expand, we are poised to recover and achieve even greater success in the biotech and wellness industries. Concerning our share structure and other changes: We made our best effort to keep a tight share structure, and support share price growth as much as possible to attract investors. However, after nearly 2 years, it is time to accept that the market reaction was not what we had hoped. At this point it has become necessary for us to utilize the public vehicle in such a way that it directly benefits the company's operations. Previously I have stated that we would not be raising the authorized any time soon. Unfortunately, I did not foresee our current predicaments, and I have to admit that I was wrong. While efforts will still be made to protect and grow the SP, all options will be on the table moving forward. Specifically, we will be raising the authorized to compensate our remaining executives, support acquisitions, and seek additional capital for expansion."

About Branded Legacy:

Branded Legacy, Inc. is a forward-thinking company specializing in the development and commercialization of biotech and wellness products. With a focus on strategic growth, innovation, and quality, the company is dedicated to enhancing lives and creating sustainable value for its shareholders.

Media Contact

Media at Branded Legacy

Phone: (321) 345-3565

Email: info@brandedlegacy.com

Website: https://brandedlegacy.com/

& definitely no communication with their shareholders.

It involved several staff members. Disgusting & hopefully they all get what they deserve.
Perhaps someone can post what Dave tweeted yesterday.

For what it’s worth I just noticed that there’s some nice positive buying going on.

Doesn’t say, but the sooner the better.

Doesn’t say, but the sooner the better.

Supposedly a PR is forthcoming.

I guess for those of us that haven’t sold off, it’s wait and see where we go from here.

Wonder when hotdawg didn’t get a call back from Dave & more or less stopped wishing us all a good morning that was a warning.

No doubt all these preferred D shares were like an anchor around Dave’s throat. Then again, perhaps Dave will pull off the surprise of the year. But will it be for the benefit of the common shareholder?

Perhaps some of the preferred D shareholders will drive this down to the same price level as KGKG and the two companies will unite. I feel sick already. Or should I say sicker.

I gather the heading towards the .01 prediction is out the window for now. So many promising press releases etc. & here we sit. Still have all my shares. Can’t pull off the bandage like some have.

From a high of .0062 to a present bid of .0005, unbelievably disappointing to say the least. Volume of 60 million and down another 25%. I call this pretty ugly.

More dumping going on.

Wonder if silence is golden, but no one even taking a chance on .0008.

A while back I was hoping for one less zero heading into the New Year, but now make that 2 less zeros.